Example: Heart Attack

Search clinical trials for: Rituximab

Total 2039 results

NCT04496037

Not yet recruiting

Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant

Conditions: Transplant; Complication, Rejection
NCT04494438

Completed

Rituximab for Idiopathic Nephrotic Syndrome

Conditions: Idiopathic Nephrotic Syndrome
NCT04494503

Not yet recruiting

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT04491721

Enrolling by invitation

Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

Conditions: Diffuse Large B Cell Lymphoma
NCT04486716

Not yet recruiting

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Conditions: Relapsing Multiple Sclerosis
NCT04481815

Recruiting

Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Conditions: PCNSL
NCT04479267

Recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma

Conditions: Diffuse Large B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC, BCL2 and BCL6 Rearrangements
NCT04480307

Recruiting

Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT04480450

Not yet recruiting

Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
NCT04464798

Not yet recruiting

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Conditions: Lymphoma
NCT04458610

Recruiting

BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patient

Conditions: Chronic Lymphocytic Leukemia (CLL)
NCT04460248

Not yet recruiting

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Conditions: Diffuse Large B Cell Lymphoma
NCT04446962

Not yet recruiting

LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

Conditions: Lymphoma, Large B-Cell, Diffuse; Central Nervous System Neoplasms, Primary
NCT04447716

Not yet recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Follicular Lymphoma; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Follicular Lymphoma; Refractory Indolent Adult Non-Hodgkin Lymphoma; Refractory Marginal Zone Lymphoma
NCT04442022

Not yet recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04435743

Recruiting

Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Conditions: Non-hodgkin Lymphoma,B Cell
NCT04436107

Not yet recruiting

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04431635

Recruiting

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Conditions: Indolent Lymphoma
NCT04432402

Recruiting

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Conditions: Diffuse Large B Cell Lymphoma
NCT04432714

Recruiting

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Conditions: DLBCL; Untreated; MYC Gene Rearrangement
NCT04433156

Recruiting

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Conditions: Marginal Zone Lymphoma
NCT04433182

Not yet recruiting

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Conditions: Diffuse Large B-cell Lymphoma
NCT04425824

Not yet recruiting

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Conditions: Diffuse Large B-cell Lymphoma; Rituximab; Toripalimab
NCT04421560

Not yet recruiting

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Conditions: Primary Central Nervous System Lymphoma; Recurrent Cancer
NCT04419389

Not yet recruiting

APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL)

Conditions: Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
NCT04416451

Not yet recruiting

Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma

Conditions: Marginal Zone Lymphoma
NCT04408638

Not yet recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Conditions: Diffuse Large B-cell Lymphoma
NCT04402580

Recruiting

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

Conditions: Nephrotic Syndrome Steroid-Dependent
NCT04404088

Recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma; Grade 3a Follicular Lymphoma
NCT04404283

Recruiting

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Conditions: Diffuse Large B-cell Lymphoma
NCT04400994

Recruiting

IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

Conditions: Pemphigus
NCT04400045

Recruiting

Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome

Conditions: Nijmegen Breakage Syndrome
NCT04384484

Not yet recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Conditions: Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
NCT04375228

Not yet recruiting

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Conditions: Immune-related Adverse Events; Advanced Solid Tumor
NCT04369183

Recruiting

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

Conditions: Focal Segmental Glomerulosclerosis; Minimal Change Disease
NCT04367610

Recruiting

Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection

Conditions: Antibody-mediated Rejection; Kidney Transplant Rejection; Graft Loss
NCT04361279

Recruiting

A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

Conditions: Diffuse Large B-Cell Lymphoma
NCT04361409

Completed

Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Conditions: Head and Neck Squamous Carcinoma
NCT04354402

Enrolling by invitation

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Conditions: Diffuse Large B Cell Lymphoma
NCT04337827

Not yet recruiting

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

Conditions: Post-transplant Lymphoproliferative Disorder
NCT04332822

Not yet recruiting

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Conditions: DLBCL; Diffuse Large B Cell Lymphoma
NCT04323956

Recruiting

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Follicular Lymphoma; Ann Arbor Stage II Marginal Zone Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage III Marginal Zone Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Ann Arbor Stage IV Marginal Zone Lymphoma; Diffuse Large B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Indolent Non-Hodgkin Lymphoma
NCT04323566

Not yet recruiting

Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement

Conditions: Obsessive-Compulsive Disorder; Obsessive-Compulsive Behavior; Schizophrenia; Delusional Disorder; Brief Psychotic Disorder; Schizo Affective Disorder; Other Psychoses; Unspecified Psychosis
NCT04323748

Not yet recruiting

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Conditions: Immune Thrombocytopenic Purpura
NCT04318678

Recruiting

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Conditions: Acute Myeloid Leukemia
NCT04319601

Recruiting

Rituximab Combined With Chidamide and Lenalidomide for r/r AITL

Conditions: Angioimmunoblastic T-cell Lymphoma; Chemotherapy Effect; Chemotherapeutic Toxicity
NCT04295733

Recruiting

Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency

Conditions: Acquired Immunodeficiency
NCT04285268

Withdrawn

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Conditions: High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
NCT04285567

Recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Conditions: Chronic Lymphocytic Leukemia (CLL)
NCT04283747

Recruiting

Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis

Conditions: Multiple Sclerosis; Hypogammaglobulinemia